BR112022005782A2 - Proteína galectina 9 estabilizada recombinante, vetor recombinante, transformante, composição farmacêutica para prevenção ou tratamento de uma doença óssea, alimento funcional de saúde para prevenção ou melhora de uma doença óssea, e, uso de uma proteína galectina 9 estabilizada recombinante - Google Patents

Proteína galectina 9 estabilizada recombinante, vetor recombinante, transformante, composição farmacêutica para prevenção ou tratamento de uma doença óssea, alimento funcional de saúde para prevenção ou melhora de uma doença óssea, e, uso de uma proteína galectina 9 estabilizada recombinante

Info

Publication number
BR112022005782A2
BR112022005782A2 BR112022005782A BR112022005782A BR112022005782A2 BR 112022005782 A2 BR112022005782 A2 BR 112022005782A2 BR 112022005782 A BR112022005782 A BR 112022005782A BR 112022005782 A BR112022005782 A BR 112022005782A BR 112022005782 A2 BR112022005782 A2 BR 112022005782A2
Authority
BR
Brazil
Prior art keywords
prevention
protein
recombinant
bone disease
pharmaceutical composition
Prior art date
Application number
BR112022005782A
Other languages
English (en)
Inventor
Ho Song Dong
Original Assignee
Gbiologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gbiologics Inc filed Critical Gbiologics Inc
Priority claimed from PCT/KR2020/015782 external-priority patent/WO2021096217A1/ko
Publication of BR112022005782A2 publication Critical patent/BR112022005782A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1732—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PROTEÍNA GALECTINA 9 ESTABILIZADA RECOMBINANTE, VETOR RECOMBINANTE, TRANSFORMANTE, COMPOSIÇÃO FARMACÊUTICA PARA PREVENÇÃO OU TRATAMENTO DE UMA DOENÇA ÓSSEA, ALIMENTO FUNCIONAL DE SAÚDE PARA PREVENÇÃO OU MELHORA DE UMA DOENÇA ÓSSEA, E, USO DE UMA PROTEÍNA GALECTINA 9 ESTABILIZADA RECOMBINANTE. A presente invenção refere-se a uma composição farmacêutica incluindo uma proteína galectina 9 recombinante estabilizada para prevenção ou tratamento de uma doença óssea, particularmente refere-se a uma composição farmacêutica para prevenção ou tratamento de uma doença óssea incluindo artrite reumatoide, que inclui uma proteína galectina 9 recombinante estabilizada em que aminoácidos de peptídeos de ligação são excluídos e aminoácidos de domínios C-terminais (CCRD) são excluídos ou substituídos, como ingrediente ativo.
BR112022005782A 2019-11-11 2020-11-11 Proteína galectina 9 estabilizada recombinante, vetor recombinante, transformante, composição farmacêutica para prevenção ou tratamento de uma doença óssea, alimento funcional de saúde para prevenção ou melhora de uma doença óssea, e, uso de uma proteína galectina 9 estabilizada recombinante BR112022005782A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190143752 2019-11-11
PCT/KR2020/015782 WO2021096217A1 (ko) 2019-11-11 2020-11-11 재조합 안정화 갈렉틴 9 단백질을 포함하는 류마티스 관절염 및 골질환 예방 또는 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
BR112022005782A2 true BR112022005782A2 (pt) 2022-10-11

Family

ID=76142932

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005782A BR112022005782A2 (pt) 2019-11-11 2020-11-11 Proteína galectina 9 estabilizada recombinante, vetor recombinante, transformante, composição farmacêutica para prevenção ou tratamento de uma doença óssea, alimento funcional de saúde para prevenção ou melhora de uma doença óssea, e, uso de uma proteína galectina 9 estabilizada recombinante

Country Status (4)

Country Link
KR (1) KR102267413B1 (pt)
CN (1) CN115605217A (pt)
BR (1) BR112022005782A2 (pt)
CA (1) CA3157954A1 (pt)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268324B2 (en) * 2004-03-29 2012-09-18 Galpharma Co., Ltd. Modified galectin 9 proteins and use thereof
JP5888761B2 (ja) 2012-11-20 2016-03-22 国立大学法人 香川大学 ガレクチン９の改変タンパク質

Also Published As

Publication number Publication date
CN115605217A (zh) 2023-01-13
KR20210056927A (ko) 2021-05-20
KR102267413B1 (ko) 2021-06-21
CA3157954A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
MX2022013526A (es) Degradadores de proteinas y usos de los mismos.
EP3533461A3 (en) Prame derived peptides and immunogenic compositions comprising these
BR112013013548B8 (pt) Proteína de fusão anticancerígena
BR112019008349A2 (pt) composição de peptídeos, e, utilização de uma composição.
TW201613958A (en) MIC-1 fusion proteins and uses thereof
CY1119976T1 (el) Μιμητικα καλσιτονινης για την αντιμετωπιση ασθενειων και διαταραχων
MX2017004488A (es) Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
EA200901459A1 (ru) Реконструированные поверхностно-активные вещества, имеющие улучшенные свойства
CY1113117T1 (el) Ηlα-α*3303-περιορισμενο wt1 πεπτιδιο και φαρμακευτικη συνθεση η οποια περιλαμβανει αυτο το ιδιο
MY161664A (en) Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
MX2020011333A (es) Uso terapeutico de proteinas morfogeneticas oseas.
MX2020000018A (es) Potencializacion de componentes sanguineos de actividad anti-bacteriana de proteina litica y metodos y usos de estos.
WO2016210370A3 (en) Synthetic peptide compounds and methods of use
NZ759601A (en) Aggrecan binding immunoglobulins
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
WO2019045248A3 (ko) 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
MX2020008902A (es) Analogos de compstatina y sus usos medicos.
MX2017016227A (es) Peptidos anti-infecciosos de amplio espectro.
ATE540971T1 (de) Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
WO2010011994A3 (en) Polypeptides and uses thereof
BR112022005782A2 (pt) Proteína galectina 9 estabilizada recombinante, vetor recombinante, transformante, composição farmacêutica para prevenção ou tratamento de uma doença óssea, alimento funcional de saúde para prevenção ou melhora de uma doença óssea, e, uso de uma proteína galectina 9 estabilizada recombinante
Ryu et al. Potential beneficial effects of marine peptide on human neuron health
MX2022003598A (es) Composicion farmaceutica, que comprende la proteina galectina 9 recombinante estabilizada, para la prevencion o el tratamiento de la artritis reumatoide y enfermedades oseas.
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.